BSE filing, NSE: BCCFUBA. Summary written from the filing by ALFA Finder's alert engine.
BCC Fuba India Ltd: key numbers
- Share price
- ₹288.50
- Market cap
- ₹571.9 Cr
- Revenue (annual)
- ₹72.65 Cr
- Net profit (annual)
- ₹5.82 Cr
- P/E (TTM)
- 69.4×Sector 42.3×
- Promoter holding
- 32.34%+0.00% QoQ
- FII holding
- 0.00%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from BCC Fuba India Ltd
All →BCC Fuba India Capital Structure Change
BCC Fuba India completed conversion of 1,52,357 partly paid-up shares to fully paid-up upon receiving call money. Shares now tradeable under ISIN INE788D01016 effective October 30, 2026.
BCC Fuba India Other Announcement
BCC Fuba India Ltd submitted its quarterly shareholding pattern for the period ended September 30, 2026. The filing includes a routine update on promoter dematerialization efforts.
BCC Fuba India Other Announcement
BCC Fuba India Limited has filed the Regulation 74(5) confirmation certificate from its Registrar and Share Transfer Agent for the quarter ended September 30, 2026.
BCC Fuba India Capital Structure Change
BCC Fuba India's Board approved forfeiture of 8,327 partly paid-up shares for unpaid call money. The forfeited paid-up amount is Rs. 0.03 Crore.
- Value
- ₹0.03 Cr
BCC Fuba India Capital Structure Change
BCC Fuba India converted 1,52,468 partly paid-up rights shares to fully paid-up after receiving ₹0.58 Crore in call money. Paid-up capital now stands at ₹19.90 Crore.
- Value
- ₹0.58 Cr
BCC Fuba India Annual General Meeting
BCC Fuba India Limited held its 40th Annual General Meeting on September 1, 2026, to conduct routine shareholder business and resolutions.
Other acquisition announcements
All →Kalpataru Acquisition Worth ₹52.55 Cr
Kalpataru's subsidiary KPL approved acquiring 16.67% of step-down subsidiaries AREPL and AREDPL for ₹52.55 Crore. This makes them wholly owned, giving Kalpataru 100% of Kalpataru Parkcity project cash flows at Thane.
- Value
- ₹52.55 Cr
- Execution
- 60 days, subject to receipt of requisite approvals
Zydus Lifesciences Acquisition Worth ₹84 Cr
Zydus Lifesciences acquired Sterling Biotech's API business for Rs. 84 Crore via slump sale. The deal covers fermentation-based API products and is completed.
- Value
- ₹84.00 Cr
Zydus Lifesciences Acquisition Worth ₹167 Cr
Zydus Lifesciences completed acquisition of Sterling Biotech's API business for Rs. 167 Crore. The slump sale of fermentation-based API products strengthens its manufacturing portfolio.
- Value
- ₹167.0 Cr
Zydus Lifesciences Acquisition
Zydus Lifesciences completed its acquisition of Sterling Biotech's API business under a September 2024 Business Transfer Agreement. No transaction value was disclosed in this filing.
Arvaya Healthcare Acquisition
Arvaya Healthcare completed the acquisition of 100% equity in Sushodha Institute of Gastroenterology Private Limited on 1 November 2026. The target is now a wholly-owned subsidiary, with no consideration amount disclosed.
Affle 3I Acquisition Worth ₹3,990 Cr
Affle 3i's step-down subsidiary will acquire Perion Network in an all-cash deal valued at about ₹3,990 Crore. Closing is expected in early 2027.
- Value
- ₹3,990 Cr
- Execution
- Expected to close in early 2027